Page 166 - Ghidul Serviciilor Medicale Synevo, Ediția 2, Volum 2

10 MARKERI TUMORALI GHIDUL SERVICIILOR MEDICALE
VICIILOR
MEDICALE
GHIDUL
SER
CUPRINS
SYNEVO
LABORA
T
OARELOR
AL
AL LABORATOARELOR SYNEVO
CALEA 4 NMP22 NEGATIV Rezultat: cel mai probabil o tumoră
fără invazie musculară
CISTOSCOPIE POZITIVĂ → Acţiune: programare pentru biopsie
şi tratament
Limite şi interferenţe
Un rezultat pozitiv nu trebuie utilizat ca evidenţă a afectării maligne a tractului urinar, fără a fi
coroborat cu procedurile standard de diagnostic .
11
Vor fi folosite aceleaşi criterii clinice de excludere ca cele menţionate la testul NMP22 cantitativ .
14

Bibliografie
1. A. Zippe, C. Pandrangi, L, Agarwa L - NMP22 is a Sensitive, Cost-Effective Test in Patients at
Risk for Bladder Cancer. In Journal of Urology 161: 62-65, January 1999.
2. Del Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, Trinchieri A, Zanetti G,
Serrago M, Pisani E. - Evaluation of Urinary Level of NMP22 as a Diagnostic Marker for Stage
pTa-pTl Bladder Cancer: Comparison with Urinary Cytology and BTA Test. In Eur Urol 1999;
35:93-97.
3. Grossman et al. In JAMA 293:810-816, 2005.
4. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care
proteomic assay. In JAMA, 2005; 293:810-816.
5. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a
point-of-care proteomic assay. In JAMA 2006; 295:299-305.
6. Grossman HB and the NMP22 Clinical Investigation Group Surveillance of patients with a history
of bladder cancer using a point-of-care proteomic assay. Program and abstracts of the American
Urological Association 2006Annual Meeting; May 20-25, 2006; Atlanta, Georgia.
7. H. Akaza, N. Miyanaga, et al. - Evaluation of Urinary NMP22 (Nuclear Matrix Protein 22) as
a Diagnostic Marker for Urothelial Cancer - Screening for Urothelial Cancer in Patients with
Microscopic Hematuria. In Jpn J Cancer chemotherapy 24(7): 837-842, 1997.
8. Katz G, Messing EM. Diagnosis of bladder cancer using a point of care proteomic assay: a
multicenter study. In J Urol. 2005;173(4 suppl):230.
9. Kevin M Tomera. NMP22 BladderCheck Test: point-of-care technology with life- and money-
saving potential. In Expert Rev.Mol. Diagn. 4(6), 783-794 (2004).
10. Laborator Synevo. Referinţele specifice tehnologiei de lucru utilizate. 2010. Ref Type: Catalog.
11. Laboratory Corporation of America. Directory of Services and Interpretive Guide. Nuclear Matrix
Protein (NMP) 22. www.labcorp.com 2010. Ref Type: Internet Communication.
12. Landmann J, Chang Y, Kavalier E, Droller MJ, Liu BC-S - Sensitivity and Specificity of NMP22,
Telomerase, and BTA in the Detection of Human Bladder Cancer. In Urology 52(3): 398-402,
September, 1998.
13. N. Miyanaga, H. Akaza et al. - Clinical Evaluation of Nuclear Matrix Protein 22 (NMP22) in Urine
as a Novel Marker for Urothelial Cancer. In Eur Urology 31: 163-168,1997.
14. Sharma S, Zippe C, Pandrangi L, Nelson D, Agarwal - A Exclusion Criteria Enhance the
Specificity and Positive Predictive Value of NMP22 and BTA STAT. Journal of Urology 162:53-
57, July 1999.

16
166 6